1018-00008 · Penterra Pharmaceuticals Corp · MAE Analysis & Termination

delaware-mae-case-law-survey.docx DOCUMENT M&A / Corporate

41 / 75 ← → ✕

MEMORANDUM

PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT

TO: Oliver Mackenzie, Partner, Mergers & Acquisitions

FROM: Derek Okonkwo, Associate, Mergers & Acquisitions

DATE: August 27, 2024

RE: Survey of Delaware Material Adverse Effect Case Law — Application to Penterra Pharmaceuticals Corp. / Veridian Biosciences, Inc. Transaction

Matter No.: 1018-00008

Client: Penterra Pharmaceuticals Corp.

Right-click to update Table of Contents

I. Executive Summary and Purpose

This memorandum surveys Delaware Court of Chancery and Delaware Supreme Court jurisprudence on the interpretation and application of material adverse effect ("MAE") provisions in the context of mergers and acquisitions. The memorandum is organized to (a) set forth the governing legal standards that Delaware courts have articulated over the past two decades, (b) analyze each of the principal Delaware decisions addressing MAE claims in detail, and (c) apply the resulting analytical framework to the facts of the Penterra Pharmaceuticals Corp. ("Penterra") and Veridian Biosciences, Inc. ("Veridian") transaction.

This memorandum has been prepared at the request of Oliver Mackenzie in connection with our ongoing analysis of whether the Marlowe Asset Management-2 Phase II clinical trial interim data readout for Veridian's lead candidate, VRD-4187, released on August 14, 2024, and the subsequent partial clinical hold imposed by the U.S. Food and Drug Administration ("FDA") on Investigational New Drug Application No. 154832 (IND 154832), imposed on August 22, 2024, together constitute a "Material Adverse Effect" as that term is defined in Section 1.1 of the Stock Purchase Agreement dated June 10, 2024, by and among Penterra Pharmaceuticals Corp., Veridian Biosciences, Inc., and the Sellers identified therein (the "SPA").

Transaction Overview. Pursuant to the SPA, Penterra agreed to acquire one hundred percent (100%) of the outstanding capital stock of Veridian for an aggregate cash purchase price of $900,000,000 (the "Purchase Price"). The SPA includes a no-MAE closing condition at Section 7.2(b) and a bring-down condition at Section 7.2(a), the latter of which requires that the Sellers' representations and warranties be true and correct as of the Closing Date, qualified in each case to the MAE standard. The Outside Date for the transaction is December 10, 2024.

Key Finding. Delaware courts place an extraordinarily heavy burden on buyers seeking to invoke MAE clauses to avoid closing obligations in acquisition agreements. Prior to 2018, no Delaware court in a reported decision had ever found that a material adverse effect had occurred. However, the 2018 decision in Akorn, Inc. v. Fresenius Kabi AG, issued by Vice Chancellor Laster of the Court of Chancery and subsequently affirmed by the Delaware Supreme Court, established that an MAE finding is not impossible and set forth a comprehensive four-step analytical framework for evaluating MAE claims. When that framework is properly applied to the present facts — the severity and breadth of the adverse clinical safety data, the non-significant efficacy results, the FDA partial clinical hold, and Veridian's status as a clinical-stage company whose enterprise value is principally derived from VRD-4187 — there is a credible basis to support Penterra's position that a Material Adverse Effect has occurred within the meaning of the SPA.

Scope and Limitations. This memorandum is intended to serve as a case law survey and preliminary analytical framework. It is designed to inform the comprehensive, fact-intensive MAE analysis being conducted separately, which will be addressed in a forthcoming memorandum applying the legal standards identified herein to the specific documentary and expert evidence relevant to the Penterra–Veridian transaction. This memorandum does not address in detail the parallel representations bring-down analysis or the ordinary course covenant compliance analysis, each of which will be treated in separate memoranda.

II. Background: The MAE Provision in the Penterra–Veridian SPA

A. Definition of Material Adverse Effect (SPA § 1.1)

Section 1.1 of the SPA defines "Material Adverse Effect" as follows:

"Material Adverse Effect" means any event, change, development, occurrence, condition, or effect that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (a) the business, results of operations, financial condition, or assets of the Company, taken as a whole, or (b) the ability of the Sellers to consummate the Transactions contemplated hereby.

This definition follows the standard two-prong formulation that is prevalent in contemporary acquisition agreements. The first prong — encompassing the business, results of operations, financial condition, or assets of the Company — is the provision most directly implicated by the VRD-4187 clinical data and FDA action. The second prong — addressing the Sellers' ability to consummate the Transactions — is potentially relevant to the extent that the FDA's partial clinical hold or related regulatory developments affect the ability of the Sellers to perform their obligations under the SPA, although our analysis focuses primarily on the first prong.

The definition is both backward-looking ("has had") and forward-looking ("would reasonably be expected to have"). The inclusion of the forward-looking element is significant in the present context. Even if the full financial and commercial effects of the Marlowe Asset Management-2 data and FDA hold have not yet been realized as of the date of this memorandum, the question is whether those events "would reasonably be expected to have" a material adverse effect on Veridian's business, results of operations, financial condition, or assets, taken as a whole. As discussed in Part IV below, Delaware courts applying the forward-looking element of the MAE definition have looked to whether the adverse developments are reasonably expected to be durationally significant and to substantially impair the target's long-term earnings potential or enterprise value.

The phrase "taken as a whole" requires that the MAE analysis be conducted with reference to the Company's entire business, not isolated components thereof. As applied to Veridian, however, this requirement does not diminish the significance of the VRD-4187 events, because Veridian is a clinical-stage company with no revenue, 148 employees, and a pipeline principally centered on VRD-4187 as its lead candidate. For practical purposes, the "taken as a whole" analysis of Veridian converges almost entirely on VRD-4187 and its development prospects.

B. Carveouts

The MAE definition in SPA § 1.1 contains seven enumerated carveouts. Under these carveouts, the following categories of events, changes, developments, occurrences, conditions, or effects are excluded from the determination of whether a Material Adverse Effect has occurred:

(i) changes in general economic or political conditions;

(ii) conditions generally affecting the biotechnology or pharmaceutical industries;

(iii) changes in applicable law or in generally accepted accounting principles ("GAAP") or in the interpretation or enforcement thereof;

(iv) pandemics, epidemics, or disease outbreaks (including COVID-19 and any similar public health emergencies) or any governmental or regulatory responses thereto;

(v) natural disasters, weather events, acts of God, acts of war (whether or not declared), armed hostility, sabotage, or terrorism;

(vi) changes in the financial, banking, or securities markets generally (including any disruption thereof or any changes in prevailing interest rates, exchange rates, or commodity prices); and

(vii) the announcement or pendency of the Transactions contemplated by this Agreement, including the impact thereof on the relationships, contractual or otherwise, of the Company with employees, customers, suppliers, partners, or other third parties.

Carveouts (i) through (vi) are subject to a disproportionate impact exception. Specifically, the SPA provides that the foregoing carveouts shall not apply to the extent that the relevant event, change, or effect disproportionately affects the Company relative to other companies of comparable size and scope operating in the biotechnology industry. This exception preserves the buyer's ability to invoke the MAE clause even where the underlying cause of the adverse event might otherwise fall within a general carveout, provided that the target has been disproportionately affected relative to its industry peers.

Critically, and of particular significance to the present analysis, there is no carveout for company-specific clinical trial results, adverse clinical events, or regulatory actions specific to a company's proprietary products or pipeline candidates. The absence of such a carveout is notable because sophisticated parties negotiating acquisition agreements in the life sciences sector sometimes include carveouts for "the results of clinical trials" or "regulatory actions specific to the Company's products." The negotiating history of the SPA, to the extent it is relevant and admissible, may shed light on whether such a carveout was proposed and rejected. In any event, the absence of such a carveout in the executed SPA means that company-specific clinical trial failures and targeted FDA regulatory actions remain within the scope of the MAE definition.

C. Closing Conditions Implicated

Three closing conditions in the SPA are directly relevant to the MAE analysis:

Section 7.2(a) — Bring-Down of Sellers' Representations and Warranties. This condition requires that the representations and warranties of the Sellers set forth in the SPA shall be true and correct in all respects (or, where qualified by materiality or Material Adverse Effect, in all respects as so qualified) as of the date of the SPA and as of the Closing Date as though made on and as of the Closing Date (except for representations and warranties that address matters only as of a specified date, which need only be true and correct as of such specified date). The bring-down is qualified to the Material Adverse Effect standard — that is, the representations and warranties need not be literally true in every particular, but any inaccuracies must not, individually or in the aggregate, constitute a Material Adverse Effect. Under Akorn, the bring-down condition is analyzed independently from the no-MAE condition described below.

Section 7.2(b) — No Material Adverse Effect. This condition provides that, since the date of the Agreement (June 10, 2024), no Material Adverse Effect shall have occurred that is continuing as of the Closing Date. This is the provision most directly implicated by the VRD-4187 clinical data and FDA hold. The phrase "that is continuing as of the Closing Date" is significant: it provides Veridian with an argument that if the FDA hold were lifted and the clinical program restarted prior to closing, the MAE might not be "continuing." However, as discussed below, even if the hold were lifted, the fundamental impairment to VRD-4187's risk-benefit profile and commercial prospects would persist given the severity of the safety data.

Section 8.1(d) — Buyer's Termination Right. This provision grants the Buyer a right to terminate the SPA if the Buyer's closing conditions set forth in Section 7.2 are incapable of being satisfied by the Outside Date (December 10, 2024), provided that Penterra is not then in material breach of the SPA and that Penterra has provided Veridian with written notice of such failure and the failure has not been cured within thirty (30) days following the date of such notice. Penterra's Deficiency Notice, issued on September 6, 2024, initiates this notice-and-cure period.

D. Factual Context

The following summary of the key factual developments is drawn from the Marlowe Asset Management-2 interim data report, the FDA correspondence, and other materials made available to this firm. A more detailed factual analysis will be contained in the forthcoming comprehensive MAE memorandum.

Marlowe Asset Management-2 Phase II Interim Data (August 14, 2024). On August 14, 2024, the Data Monitoring Committee ("DMC") for the Marlowe Asset Management-2 Phase II clinical trial conducted a pre-specified interim analysis. The results revealed the following:

• Safety: The treatment arm exhibited a 23.4% incidence of Grade 3 or higher cytokine release syndrome ("CRS"), compared to 4.1% in the control arm. There were seven (7) treatment-related deaths in the treatment arm (3.6% of enrolled patients) compared to one (1) death in the control arm (0.5%).

• Efficacy: The overall response rate ("ORR") was 31.4% in the treatment arm compared to 28.9% in the control arm, with a p-value of 0.58. This result is not statistically significant, meaning the data did not demonstrate a meaningful efficacy advantage for VRD-4187 over the standard of care comparator.

In combination, the data indicate that VRD-4187 in its current formulation and dosing regimen demonstrates no statistically significant efficacy benefit while carrying a dramatically elevated safety risk — a risk-benefit profile that, on its face, is inconsistent with an approvable New Drug Application ("NDA") pathway.

FDA Partial Clinical Hold (August 22, 2024). On August 22, 2024, the FDA imposed a partial clinical hold on IND 154832 covering the Marlowe Asset Management-2 trial. A partial clinical hold suspends some but not all clinical work under the IND; in this case, new enrollment in the Marlowe Asset Management-2 trial has been halted pending FDA review of the safety data and Veridian's response. The partial clinical hold has no predetermined end date; its resolution requires Veridian to submit a complete response to the FDA's clinical hold letter addressing the identified safety concerns, after which the FDA will have thirty (30) days to review and either lift the hold or request additional information.

Veridian's Status as a Clinical-Stage Company. Veridian is a clinical-stage biopharmaceutical company with zero revenue for fiscal year 2023 (and all prior periods), approximately 148 employees, and a pipeline principally centered on VRD-4187 as its lead and most advanced therapeutic candidate. Veridian has raised approximately $420 million in total venture capital financing. The $900 million acquisition price negotiated by the parties was predicated principally on the expected commercial value of VRD-4187 and its anticipated regulatory and market prospects.

Procedural History. On September 6, 2024, Penterra delivered a Deficiency Notice to Veridian identifying the Marlowe Asset Management-2 interim data and FDA partial clinical hold as constituting a Material Adverse Effect under the SPA and asserting that the closing conditions in Sections 7.2(a) and 7.2(b) were not capable of being satisfied. On September 13, 2024, Veridian delivered a written response disputing that a Material Adverse Effect had occurred and contending that the clinical data are preliminary and subject to remediation through its ongoing protocol amendments.

III. The Legal Standard for Material Adverse Effect Under Delaware Law

A. General Principles

Material adverse effect clauses are among the most significant risk-allocation mechanisms in acquisition agreements. They operate principally in two contexts: (1) as a qualification to representations and warranties, limiting the scope of those representations to matters that are material to the target's business; and (2) as a closing condition, permitting the buyer to refuse to close the transaction if an MAE has occurred between signing and closing. The present analysis focuses primarily on the second context — the no-MAE closing condition — although the representations bring-down analysis (which itself is qualified to the MAE standard) is also implicated, as discussed in Part II.C above.

Delaware courts interpret MAE clauses according to their plain language, giving effect to the parties' contractual allocation of risk as expressed in the text of the agreement. Where the contractual language is unambiguous, the court applies that language in accordance with its ordinary meaning, informed by the commercial context in which the agreement was negotiated and executed. As Vice Chancellor Strine observed in the foundational IBP decision, the purpose of an MAE clause is "to protect the acquiror from the occurrence of unknown events that substantially threaten the overall earnings potential of the target in a durationally-significant manner." In re IBP, Inc. S'holders Litig., 789 A.2d 14, 68 (Del. Ch. 2001).

The buyer bears the burden of proving that a material adverse effect has occurred. This allocation of the burden of proof is well-established in Delaware jurisprudence and reflects the policy judgment that the MAE standard is designed as a backstop against unexpected and severe adverse developments, not as a general exit mechanism for buyers experiencing doubts about a transaction. The buyer must demonstrate, by a preponderance of the evidence, that the facts satisfy each element of the contractual MAE definition.

The standard for determining whether an event or development constitutes an MAE is qualitative and contextual. Delaware courts have consistently declined to adopt a bright-line percentage test or numerical threshold for materiality in the MAE context. Instead, the analysis requires a holistic assessment of the nature, severity, duration, and reversibility of the adverse development, viewed in the context of the target company's overall business and the reasonable expectations of the parties at the time of signing. This contextual approach necessarily means that the significance of a given adverse development will vary depending on the nature of the target's business, its industry, its financial profile, and the specific circumstances of the transaction.

Courts have historically recognized that the MAE standard is designed to protect buyers against adverse developments that are consequential to the long-term value of the target, not against short-term or transient fluctuations in performance. This principle — the "durational significance" requirement — is the single most important analytical tool in the Delaware MAE framework and is discussed in greater detail in Part III.B below.

B. Durational Significance

The concept of durational significance is the central pillar of Delaware MAE jurisprudence. First articulated by Vice Chancellor Strine in IBP, the principle holds that an adverse effect must be "durationally significant" in order to constitute a material adverse effect — that is, it must substantially threaten the overall earnings potential of the target in a manner that is significant when measured not in terms of short-term results but rather from the longer-term perspective of a reasonable acquiror.

The durational significance standard serves a critical gatekeeping function. It distinguishes between, on the one hand, temporary setbacks, cyclical downturns, or transient market fluctuations that a reasonable buyer would expect to encounter and weather over the course of owning the target business, and, on the other hand, fundamentally value-destructive events that permanently or semi-permanently impair the target's ability to generate earnings or achieve its expected commercial potential.

The concept evolved through several cases in the years following IBP. In Hexion Specialty Chemicals, Inc. v. Huntsman Corp., 965 A.2d 715 (Del. Ch. 2008), the court applied the durational significance standard in the context of a financial downturn, concluding that the target's declining performance was attributable to macroeconomic conditions that did not warrant an MAE finding. In Akorn, Inc. v. Fresenius Kabi AG, C.A. No. 2018-0300-JTL (Del. Ch. Oct. 1, 2018), aff'd, 198 A.3d 724 (Del. 2018), Vice Chancellor Laster reaffirmed and refined the standard, finding that the target's approximately 86% decline in EBITDA sustained over multiple quarters, combined with pervasive regulatory violations that impaired its future operating capacity, was "durationally significant" in a manner that no reasonable acquiror could dismiss as temporary.

Courts assess durational significance by looking to the long-term horizon of the reasonable buyer — typically measured in years rather than months. A decline in a single quarter's earnings, even a substantial one, is generally insufficient to satisfy the durational significance standard if the decline is attributable to temporary or cyclical factors. Conversely, an adverse development that permanently impairs a core asset or capability of the target — such as the loss of a key regulatory approval, the permanent shutdown of a critical manufacturing facility, or, as in Akorn, the discovery of pervasive data integrity violations — is more likely to be found durationally significant because its effects will persist indefinitely.

The durational significance standard presents particular analytical challenges in the context of clinical-stage companies. For a target with no revenue and no current earnings, the concept of a "decline in earnings potential" must be adapted to focus on the impairment of expected future value derived from the company's pipeline. Where the target's enterprise value is derived principally from a single clinical program — as is the case with Veridian and VRD-4187 — a severe adverse clinical event that fundamentally impairs the lead candidate's development prospects can be analogized to a devastating and sustained decline in earnings for a revenue-generating company.

C. The "Reasonable Acquiror" Standard

The MAE analysis is conducted from an objective standpoint: the question is whether a reasonable acquiror would view the adverse development as materially altering the value proposition of the target. The buyer's subjective motivations — including so-called "buyer's remorse" — are irrelevant. See Hexion, 965 A.2d at 738 (rejecting buyer's MAE claim in part because of evidence that the buyer was seeking to escape the transaction for reasons unrelated to the target's performance).

The reasonable acquiror standard is not measured solely by reference to short-term financial results. Rather, the hypothetical reasonable acquiror is assumed to be a sophisticated market participant purchasing the long-term earnings potential of the target business. This acquiror is presumed to understand the industry dynamics, business cycles, and inherent risks associated with the target's business, and to have priced those known risks into the transaction at signing. The MAE clause protects against unknown or unforeseen developments that materially alter the value that the reasonable acquiror expected to receive.

The target is evaluated "as a whole" — not in isolation by individual products, assets, or business segments. For a diversified company with multiple revenue streams, an adverse event affecting one product line might not constitute an MAE if the company's other businesses remain healthy. However, for a single-product or clinical-stage company such as Veridian, the lead asset may effectively be the whole company. In such circumstances, the "taken as a whole" qualifier does not provide meaningful insulation, because an adverse event affecting the lead asset necessarily affects the company as a whole.

D. Magnitude of the Adverse Change

Delaware courts have declined to establish a fixed numerical threshold for the magnitude of adverse change required to constitute an MAE. The analysis depends on the totality of the circumstances, including the nature of the adverse development, the target's business and financial profile, the industry context, and the parties' reasonable expectations at signing.

That said, the case law provides some guideposts. In IBP, Vice Chancellor Strine noted that the buyer's expert suggested a decline of approximately 40% or more in earnings might constitute an MAE, and the court appeared to treat that range as a reasonable benchmark — while emphasizing that it was not adopting a rigid standard. 789 A.2d at 67. In Akorn, the approximately 86% decline in EBITDA was, in the court's view, clearly sufficient to meet the magnitude requirement, even standing alone. The court noted that a decline of that magnitude was "many times greater" than the thresholds that practitioners and commentators have discussed as potentially material. Akorn, C.A. No. 2018-0300-JTL, at *166.

For clinical-stage biotechnology companies with no revenue, the traditional earnings-based metrics used to measure the magnitude of adverse change are inapplicable. There are no historical earnings, EBITDA, or revenue figures against which to calculate a percentage decline. Instead, the analysis must focus on the impairment of expected future value derived from the pipeline. This may require resort to discounted cash flow analyses, comparable transaction valuations, probability-weighted pipeline valuations, or other methodologies that can quantify the extent to which the adverse clinical events have reduced the expected commercial value of the target's pipeline assets — and, by extension, the enterprise value of the company. The translation of these analytical tools into the MAE framework for clinical-stage companies is an area of limited Delaware authority, as discussed further in Part IV.D below.

IV. Key Delaware Cases

This Part surveys the principal Delaware decisions addressing MAE claims in acquisition transactions. The cases are organized chronologically and thematically: pre-Akorn jurisprudence (establishing the high standard for MAE claims), the Akorn decision (the watershed moment), and post-Akorn jurisprudence (applying and refining the Akorn framework).

A. Pre-Akorn Jurisprudence: The Historical Reluctance to Find MAE

1. In re IBP, Inc. Shareholders Litigation (Del. Ch. 2001)

In re IBP, Inc. Shareholders Litigation, 789 A.2d 14 (Del. Ch. 2001), is the foundational Delaware decision on MAE analysis and remains one of the most frequently cited opinions in this area.

Facts. Fenmore Partners LLC ("Tyson") agreed to acquire IBP, Inc. ("IBP"), a major meat processing company, in a transaction valued at approximately $3.2 billion. After signing the merger agreement, IBP reported significant earnings declines in the fourth quarter of 2000 and the first quarter of 2001. IBP's earnings in Q4 2000 were approximately 64% lower than the prior year's comparable quarter. In addition, accounting irregularities were discovered at DFG Foods, an IBP subsidiary, involving improper revenue recognition. Tyson sought to invoke the MAE clause in the merger agreement and to terminate the transaction, arguing that the combination of the earnings decline and the accounting irregularities constituted a material adverse effect.

Holding. Vice Chancellor Strine held that no material adverse effect had occurred. The court found that the earnings decline, while significant on a quarter-over-quarter basis, was not durationally significant because IBP's business was inherently cyclical and seasonal. The meat processing industry was subject to well-known fluctuations driven by livestock supply cycles, commodity pricing, and weather patterns. A reasonable acquiror with knowledge of IBP's business would have understood these cyclical dynamics at the time of signing and would not have viewed a single-quarter downturn — even a severe one — as a fundamental impairment of IBP's long-term earnings potential. As to the DFG Foods accounting irregularities, the court found that the issues were confined to a subsidiary that represented a small fraction of IBP's overall business and did not rise to the level of materiality when viewed in the context of the company "as a whole."

The court also found that Tyson's real motivation was buyer's remorse — Tyson had grown concerned about its own financial capacity and strategic direction and was using the MAE clause as a pretext to exit a deal it no longer wanted. While the court noted that the buyer's subjective motivations are not directly relevant to the objective MAE analysis, Tyson's conduct undercut the credibility of its factual assertions and reinforced the court's skepticism of the MAE claim.

Key Principles Established.

Durational Significance. The IBP decision introduced the "durational significance" standard that has become the cornerstone of Delaware MAE jurisprudence. Vice Chancellor Strine held that "short-term hiccups in earnings should not suffice" to establish an MAE, because "acquirors [are] purchasing the long-term value of the business." 789 A.2d at 68. An MAE must be measured against the long-term value of the target, not against quarterly or annual fluctuations.

High Bar. The decision set a very high bar for establishing an MAE. The court's refusal to find an MAE despite a 64% quarterly earnings decline signaled to practitioners and courts alike that the threshold for an MAE finding was significantly higher than many had previously assumed.

Cyclical Risk. A reasonable acquiror is presumed to have understood the cyclical risks inherent in the target's industry at the time of signing. A downturn consistent with known cyclical patterns does not constitute an MAE.

Taken as a Whole. The adverse developments must be material to the company "as a whole," not merely to isolated segments or subsidiaries.

Relevance to Penterra–Veridian. The IBP decision is distinguishable from the Penterra–Veridian facts in several critical respects. First, IBP was a mature, revenue-generating company with a long operating history and well-understood cyclical patterns. The court's conclusion that the earnings decline was not durationally significant rested heavily on the cyclical nature of the meat processing industry — a reasonable acquiror understood that earnings would fluctuate over time and priced that volatility into the deal. Veridian, by contrast, is a clinical-stage company with $0 revenue. The VRD-4187 clinical data failure is not a "cyclical" event that a reasonable acquiror would have anticipated as part of the normal ebb and flow of the business; it is a discrete, potentially permanent impairment of the company's lead — and effectively sole — value driver.

Second, and relatedly, the IBP court's analysis focused on the target's historical financial performance and the expectation that earnings would revert to the mean over time. In the Veridian context, there is no historical earnings pattern to which the business can be expected to revert. The value of Veridian is entirely forward-looking, derived from the anticipated commercial success of VRD-4187. An adverse development that fundamentally impairs VRD-4187's development prospects does not present the same "cyclical reversion" dynamic that saved IBP.

Third, the DFG Foods accounting issues in IBP were isolated to a small subsidiary. Here, the adverse events go to the core of Veridian's only advanced clinical program and affect the single compound that constitutes substantially all of the company's enterprise value.

2. Frontier Oil Corp. v. Holly Corp. (Del. Ch. 2005)

Frontier Oil Corp. v. Holly Corp., 2005 WL 1039027 (Del. Ch. Apr. 29, 2005), provided additional guidance on the buyer's burden in establishing an MAE.

Facts. Holly Corporation ("Holly") entered into a merger agreement with Frontier Oil Corporation ("Frontier"). After signing, Frontier sought to argue that certain environmental liabilities at Holly's operations, combined with a pending SEC investigation into Holly's financial reporting practices, constituted a material adverse effect that excused Frontier from its closing obligations.

Holding. The Court of Chancery declined to find that an MAE had occurred. The court emphasized that the buyer had failed to carry its burden of demonstrating that the identified developments substantially threatened the target's long-term earnings potential. The environmental liabilities, while potentially costly, were of a type common to companies in the refining industry and had not been shown to be of a magnitude that would fundamentally impair Holly's ability to operate its business over the long term. The SEC investigation, while creating uncertainty, had not resulted in any enforcement action or restatement at the time of the decision, and the court was unwilling to treat speculative future regulatory outcomes as a present MAE.

Key Principle. The buyer must demonstrate materiality in the context of the overall enterprise, not in isolation by reference to individual liabilities, contingencies, or regulatory proceedings. A pending investigation or potential liability, without more, is generally insufficient to establish an MAE where the ultimate outcome and magnitude of the exposure remain uncertain.

Relevance to Penterra–Veridian. Frontier Oil reinforces the high burden faced by buyers invoking MAE clauses, but it is distinguishable on the facts. The environmental and SEC issues in Frontier Oil were contingent and speculative — their ultimate impact on Holly's business was uncertain. By contrast, the VRD-4187 clinical data is not speculative; it consists of actual, quantified safety and efficacy results from a controlled clinical trial, and the FDA partial clinical hold is a concrete regulatory action that has already halted enrollment in the Marlowe Asset Management-2 trial. The adverse developments here are not merely potential — they have already materialized.

3. Hexion Specialty Chemicals, Inc. v. Huntsman Corp. (Del. Ch. 2008)

Hexion Specialty Chemicals, Inc. v. Huntsman Corp., 965 A.2d 715 (Del. Ch. 2008), addressed MAE claims arising in the context of the 2008 financial crisis and provided important guidance on the operation of carveouts and the disproportionate impact exception.

Facts. Hexion Specialty Chemicals, Inc. ("Hexion"), a portfolio company of Ridgeline Investors, agreed to acquire Brundavel Corporation ("Huntsman"), a diversified chemical company, in a leveraged buyout valued at approximately $10.6 billion. After signing, the global financial crisis of 2008 caused significant disruption across the chemical industry, and Huntsman's financial performance declined materially. Hexion sought a declaratory judgment that it was not obligated to close the transaction, arguing that Huntsman had suffered an MAE and that the combined entity would be insolvent.

Holding. Vice Chancellor Lamb found that no MAE had occurred. The court concluded that Huntsman's financial decline was largely attributable to the general economic downturn and conditions affecting the chemical industry broadly — both of which fell within the carveout provisions of the merger agreement. Because the adverse effects were attributable to carved-out causes, they could not form the basis of an MAE finding unless Hexion demonstrated that Huntsman had been disproportionately affected relative to other companies in the chemical industry. The court found that Hexion had failed to carry this burden; Huntsman's performance decline was consistent with the industry-wide downturn and did not reflect disproportionate impact.

The court further found that Hexion had acted in bad faith by commissioning a solvency opinion designed to create a pretext for termination. While this finding did not directly affect the MAE analysis (which is objective), it contributed to the court's overall assessment of the equities and reinforced the principle that a buyer cannot manufacture grounds for termination.

Key Principles.

Operation of Carveouts. Industry-wide and macroeconomic downturns typically fall within the enumerated carveouts found in most MAE definitions. When the adverse effects are attributable to carved-out causes, they are excluded from the MAE analysis unless the disproportionate impact exception applies.

Disproportionate Impact Analysis. Even when a general carveout applies, the buyer may reinstate the MAE by demonstrating that the target was disproportionately affected relative to comparably situated companies. This requires a comparative analysis showing that the target's performance deteriorated more severely than that of its industry peers during the same period.

Subjective Motivations Irrelevant. The buyer's subjective motivations — including buyer's remorse, strategic shifts, or financing difficulties — are irrelevant to the objective MAE analysis. However, evidence of bad faith may inform the court's assessment of the buyer's credibility and the equities of the case.

Relevance to Penterra–Veridian. Hexion is significant to the Penterra–Veridian analysis principally for its treatment of carveouts and the disproportionate impact exception. The SPA in the present transaction contains similar carveout provisions, including carveouts for general economic conditions and conditions affecting the biotechnology or pharmaceutical industries generally. However, unlike the financial crisis at issue in Hexion, the VRD-4187 clinical data failure and FDA hold are company-specific events. They are not attributable to general economic conditions, industry-wide trends, or macroeconomic disruptions. Accordingly, the carveout analysis should not present a barrier to Penterra's MAE claim. To the extent Veridian attempts to invoke the industry-wide carveout — arguing, for example, that clinical trial failures are an inherent risk of the biotechnology industry — the disproportionate impact exception would reinstate the MAE, as the VRD-4187 events are specific to Veridian's proprietary compound and clinical program.

4. Additional Pre-Akorn Cases

Several additional pre-Akorn decisions further illustrate the pattern of buyer difficulty in establishing MAE claims under Delaware law. While a comprehensive treatment of each is beyond the scope of this memorandum, the following brief summaries are instructive:

Genworth Financial, Inc. v. AGL Resources, Inc. In this matter, the parties disputed whether certain adverse regulatory developments constituted an MAE under the merger agreement. Consistent with the broader pattern, the court declined to find an MAE, emphasizing the high burden on the buyer and the target's continued operational viability notwithstanding the regulatory challenges.

Other Decisions. In the period between IBP (2001) and Akorn (2018), no Delaware court in a reported decision found that a material adverse effect had occurred. This seventeen-year streak of buyer defeats created a perception — widespread among practitioners — that the MAE clause was essentially a "dead letter" provision that existed in merger agreements as a matter of drafting convention but could never realistically be invoked. The Akorn decision would prove that perception wrong.

The significance of this unbroken record of seller victories cannot be overstated. It means that any buyer invoking an MAE clause in Delaware faces not only the formal legal burden of proof but also the practical burden of overcoming a strong judicial presumption — born of historical experience — that MAE claims are disfavored. Penterra must be prepared to demonstrate that the present facts are truly exceptional, on the order of Akorn itself.

B. The Akorn Decision: The Watershed Moment

1. Akorn, Inc. v. Fresenius Kabi AG (Del. Ch. 2018; affirmed Del. S. Ct. 2018)

Akorn, Inc. v. Fresenius Kabi AG, C.A. No. 2018-0300-JTL, 2018 WL 4719347 (Del. Ch. Oct. 1, 2018), aff'd, 198 A.3d 724 (Del. 2018), is the most important Delaware decision on MAE law and provides the governing analytical framework for evaluating MAE claims in post-signing disputes.

Facts in Detail. In April 2017, Fresenius Kabi AG ("Fresenius"), a global healthcare company, agreed to acquire Akorn, Inc. ("Akorn"), a specialty generic pharmaceutical company, for approximately $4.75 billion in a reverse triangular merger. The merger agreement contained a standard MAE clause with customary carveouts and closing conditions.

After signing, Akorn experienced a catastrophic deterioration on two fronts. First, Akorn's financial performance collapsed. In the quarters following the signing of the merger agreement, Akorn's year-over-year EBITDA declined by approximately 86%, and revenues dropped by approximately 25% to 34% depending on the measurement period. These declines were sustained over multiple consecutive quarters and were not attributable to seasonal or cyclical factors. Akorn's management attributed the decline to increased generic drug competition, pricing pressure, and the loss of certain product approvals, but the magnitude of the decline far exceeded anything reasonably foreseeable at the time of signing.

Second, and independently, extensive FDA data integrity violations were discovered at multiple Akorn manufacturing facilities. Whistleblower reports led Fresenius to commission an investigation, which uncovered pervasive problems with Akorn's quality assurance and regulatory compliance systems. The investigation revealed that Akorn employees had systematically falsified data submitted to the FDA in connection with abbreviated New Drug Applications ("ANDAs"), including fabricating test results, backdating stability data, and manipulating product testing protocols. The violations were not isolated to a single facility or a small group of employees; they were systemic and affected multiple sites and product lines. The FDA data integrity issues went to the core of Akorn's ability to manufacture and sell generic pharmaceutical products — activities that constituted Akorn's entire business model.

Fresenius notified Akorn that it believed a material adverse effect had occurred and that it intended to terminate the merger agreement. Akorn filed suit seeking specific performance of the merger. The Court of Chancery conducted a five-day trial.

Holding. In a comprehensive 246-page opinion, Vice Chancellor Laster held that a material adverse effect had occurred — the first reported Delaware decision to so hold. The court found that the closing conditions in the merger agreement were not satisfied, and that Fresenius was entitled to terminate the transaction. The Delaware Supreme Court affirmed on December 7, 2018, in a brief opinion endorsing the Court of Chancery's reasoning and conclusions.

Key Principles and Analytical Framework. The Akorn decision established a comprehensive four-step framework for evaluating MAE claims under Delaware law, together with detailed guidance on each step.

(a) The Four-Step MAE Analysis. Vice Chancellor Laster organized the MAE analysis into four sequential inquiries:

Step 1: Has a Material Adverse Effect occurred within the meaning of the contractual definition? This requires application of the durational significance standard, considering both quantitative and qualitative factors.

Step 2: Does the MAE fall within one of the contractual carveouts or exceptions? If so, the effect is excluded from the MAE analysis (subject to Step 3).

Step 3: If a carveout applies, does the disproportionate impact exception reinstate the MAE? The buyer must show that the target was disproportionately affected relative to comparably situated companies.

Step 4: Did the buyer contribute to or cause the MAE such that it should be equitably estopped from invoking the MAE clause? This inquiry addresses whether the buyer's own conduct caused or materially contributed to the adverse developments.

This four-step framework has become the standard analytical structure for MAE claims in Delaware and is the framework that should be applied to the Penterra–Veridian facts.

(b) Quantitative and Qualitative Factors (Step 1). In applying the first step of the analysis, the court considered both quantitative financial metrics and qualitative operational factors.

On the quantitative side, the court found that Akorn's approximately 86% decline in EBITDA over multiple quarters was "overwhelming" and satisfied even the most stringent interpretation of the durational significance standard. The court observed that this decline was "many times greater" than the thresholds discussed by commentators and that no reasonable acquiror could view such a decline as a temporary blip. The court also noted that the decline was sustained — it persisted over multiple consecutive quarters with no indication of reversal — and was expected to continue indefinitely based on the competitive dynamics facing Akorn's product portfolio.

On the qualitative side, the court found that the pervasive FDA data integrity violations independently constituted a development of MAE magnitude. The violations went to the core of Akorn's ability to maintain its FDA-approved manufacturing operations and to market its products. The court emphasized that for a generic pharmaceutical company whose entire business model depended on regulatory compliance, the discovery of systematic data falsification was not merely a quantitative financial setback but a qualitative impairment of the company's fundamental operating capacity. The regulatory violations created a "cloud" over Akorn's business that would persist for years, impairing its ability to obtain new product approvals, retain existing approvals, and maintain its relationships with customers and regulators.

The court's treatment of qualitative factors is particularly relevant to the Penterra–Veridian analysis, where the adverse clinical data and FDA hold represent qualitative impairments to VRD-4187's development program that cannot be fully captured by traditional financial metrics.

(c) Representations Bring-Down (Analyzed Separately from MAE). Vice Chancellor Laster separately analyzed the representations bring-down condition in the merger agreement. This analysis was independent of the MAE closing condition analysis; the court found that the bring-down condition was not satisfied for reasons that partially overlapped with, but were distinct from, the MAE finding.

Specifically, the court found that Akorn's representations regarding its regulatory compliance — including representations that it had complied in all material respects with applicable FDA regulations — were inaccurate in all material respects at the time of closing. The data integrity violations rendered these representations false, and the inaccuracies were of a magnitude that constituted a Material Adverse Effect when measured against the bring-down standard.

This aspect of the Akorn decision is significant because it establishes that the no-MAE closing condition and the representations bring-down condition are independent bases for non-satisfaction of closing conditions. A buyer pursuing an MAE-related defense should assert both grounds wherever the facts support them, as Penterra has done in its Deficiency Notice.

(d) The Ordinary Course Covenant. The Akorn court also found that Akorn had breached its obligation to operate the business in the ordinary course between signing and closing. This finding provided an additional, independent ground for Fresenius to refuse to close. While the ordinary course covenant analysis is not central to this MAE case law survey, it is worth noting that the Akorn decision reinforces the principle that multiple closing conditions should be evaluated independently, as any one of them may independently support the buyer's refusal to close.

Relevance to Penterra–Veridian. Akorn is the leading precedent and the only reported Delaware case in which a court found an MAE. It provides the governing analytical framework that will be applied to the Penterra–Veridian facts. Several aspects of the comparison merit particular attention.

Distinguishing Factors. The most significant distinction between Akorn and the present case is that Akorn was a revenue-generating company with historical financial results against which the magnitude of adverse change could be directly measured. The approximately 86% decline in EBITDA was a striking, easily quantifiable figure that left no doubt about the severity of the impact. Veridian, by contrast, has $0 in revenue and no historical earnings. There is no EBITDA to decline. The quantitative analysis must therefore be conducted by reference to the impairment of expected future value — the reduction in the probability-weighted net present value of VRD-4187's commercial potential — rather than historical financial performance. This is a more complex and contested analysis, and the absence of a concrete, easily calculable percentage decline may make it harder for Penterra to establish the same degree of quantitative certainty that the Akorn court found.

Analogous Factors. Notwithstanding the foregoing distinction, several aspects of the Akorn facts are strongly analogous to the present case:

• Regulatory impairment at the core of the business. Just as the FDA data integrity violations in Akorn went to the core of Akorn's ability to manufacture and sell generic pharmaceuticals — i.e., the company's entire business — the FDA partial clinical hold on VRD-4187 goes to the core of Veridian's ability to develop and commercialize its lead product. VRD-4187 is the primary value driver in a $900 million transaction.

• Pervasiveness and systemic nature of the problems. The Akorn court emphasized the pervasive, systemic nature of the data integrity violations — they were not isolated to a single facility or product but affected multiple sites and product lines. Similarly, the VRD-4187 safety signal is not an isolated adverse event but a systemic finding across the treatment arm: 23.4% of patients experienced Grade 3 or higher CRS, and 3.6% of treatment-arm patients died. The breadth of the safety signal suggests a fundamental problem with the compound's mechanism of action or dosing, not a random or isolated occurrence.

• Single-asset dependency. While Akorn had multiple products, the court noted that the data integrity violations affected the company's ability to operate its core business. Veridian's dependency on VRD-4187 is, if anything, even more extreme — VRD-4187 is the lead candidate and the principal (if not sole) basis for the $900 million valuation. The impairment of VRD-4187 thus impairs substantially all of Veridian's enterprise value.

• Expected indefinite duration. The Akorn court found that the adverse effects were expected to persist indefinitely. Here, the FDA partial clinical hold has no fixed end date, and even if lifted, VRD-4187 would need to restart with a modified protocol, re-enroll patients, and generate entirely new safety and efficacy data — a process that would take multiple years and whose outcome is uncertain.

2. Delaware Supreme Court Affirmance of Akorn

The Delaware Supreme Court affirmed the Court of Chancery's decision in Akorn on December 7, 2018, in a relatively brief opinion. Akorn, Inc. v. Fresenius Kabi AG, 198 A.3d 724 (Del. 2018). The Supreme Court endorsed the Vice Chancellor's multi-factor analytical approach without significant modification. The court confirmed that MAE findings, while rare, are available when the underlying facts are sufficiently severe. The Supreme Court observed that the burden on the buyer remains "heavy" but is "not insurmountable," and that the trial court had properly applied the durational significance standard and the other elements of the MAE framework to the particular facts of the case.

The Supreme Court's affirmance is significant for two reasons. First, it establishes that the four-step analytical framework articulated by Vice Chancellor Laster is the governing standard for MAE claims in Delaware — it has the imprimatur of the state's highest court, not merely the Court of Chancery. Second, the Supreme Court's characterization of the buyer's burden as "heavy" but "not insurmountable" provides a useful counterpoint to the pre-Akorn perception that MAE claims were effectively impossible to prove. The Supreme Court's language signals that courts should take MAE claims seriously when the facts warrant, even if the standard remains demanding.

C. Post-Akorn Jurisprudence

1. Channel Medsystems, Inc. v. Boston Scientific Corp. (Del. Ch. 2019)

Channel Medsystems, Inc. v. Boston Scientific Corp., C.A. No. 2018-0673-AGB (Del. Ch. 2019), is a particularly significant post-Akorn decision for the Penterra–Veridian analysis because it addressed MAE claims arising from adverse clinical events in the healthcare context.

Facts. Greaves Corporation ("Boston Scientific") entered into an agreement to acquire Channel Medsystems, Inc. ("Channel"), a medical device company. After signing, a patient death occurred during a clinical trial of Channel's lead product. The FDA initiated an investigation into the circumstances of the death, and the clinical trial was suspended. Boston Scientific invoked the MAE clause in the acquisition agreement, arguing that the patient death and FDA investigation constituted a material adverse effect that excused it from closing.

Holding. The Court of Chancery found that a single adverse clinical event, while serious, did not constitute an MAE where the issue was potentially remediable and the company had other pipeline assets that contributed to its overall value. The court emphasized that the patient death, while tragic, was an isolated event that did not reflect a systemic safety problem with the product. The FDA investigation was ongoing and could potentially be resolved without permanent impairment to the product's regulatory pathway. Moreover, Channel had other products and pipeline candidates that contributed to its enterprise value, meaning that the adverse event affecting one product did not necessarily impair the company "taken as a whole."

Key Principle. Isolated clinical events may not rise to the level of MAE unless they fundamentally impair the target's long-term value. Remediability is a relevant factor — if the adverse event can reasonably be expected to be remediated through protocol modifications, additional clinical work, or other corrective measures, it is less likely to be found durationally significant.

Relevance to Penterra–Veridian. Channel Medsystems provides both favorable and unfavorable elements for Penterra's position.

Unfavorable elements: The decision establishes that adverse clinical events — including patient deaths and FDA investigations — do not automatically constitute MAE, and that remediability is a factor weighing against an MAE finding. Veridian will undoubtedly cite Channel Medsystems for the proposition that clinical setbacks are inherent to the development of novel therapeutics and that the VRD-4187 safety issues can be addressed through protocol modifications (as evidenced by Veridian's Protocol v4.0 amendment).

Favorable elements — distinguishing features: The VRD-4187 situation is materially distinguishable from Channel Medsystems in several critical respects:

• The VRD-4187 safety signal is not an isolated event involving a single patient. It is a systemic finding across the entire treatment arm: 23.4% of patients experienced Grade 3 or higher CRS, and 7 patients (3.6%) died. This is a fundamentally different situation from a single patient death.

• The VRD-4187 efficacy data is non-significant (ORR 31.4% vs. 28.9%, p = 0.58), meaning the drug failed to demonstrate an efficacy advantage over standard of care. In Channel Medsystems, the safety event was the sole problem; there was no simultaneous efficacy failure. The combination of elevated safety risk and non-significant efficacy creates a compounded problem that is far more severe.

• Channel had other pipeline assets that contributed to its enterprise value, diluting the impact of the adverse event on the company "taken as a whole." Veridian is a clinical-stage company with no revenue and no other advanced pipeline candidates. VRD-4187 is essentially the entirety of the company's value proposition.

• The remediability analysis is more problematic for VRD-4187 than for the Channel product. Even if Veridian modifies the protocol (as it has done with Protocol v4.0, reducing the dose from 1.5 mg/kg to 0.75 mg/kg and adding mandatory tocilizumab prophylaxis), the modified regimen has not been clinically validated. The dose reduction may eliminate the already non-significant efficacy signal. Remediability in this context is speculative and would require years of additional clinical development with uncertain outcomes.

2. Snow Phipps Group, LLC v. KCake Acquisition, Inc. (Del. Ch. 2021)

Snow Phipps Grp., LLC v. KCake Acquisition, Inc., C.A. No. 2020-0282-KSJM (Del. Ch. Apr. 30, 2021), addressed MAE claims arising from the COVID-19 pandemic's impact on a retail food service business.

Facts. Snow Phipps Group, LLC ("Snow Phipps") sought to invoke the MAE clause in a stock purchase agreement to avoid closing its acquisition of a restaurant and bakery business after the COVID-19 pandemic caused dramatic declines in the target's revenues and operations. The target's business was severely affected by government-mandated shutdowns, reduced consumer traffic, and operational disruptions.

Holding. The Court of Chancery found that no MAE had occurred. The court held that the pandemic-related disruptions fell squarely within the pandemic carveout contained in the MAE definition. Because the adverse effects were attributable to a carved-out cause, they could not constitute an MAE unless the buyer demonstrated disproportionate impact relative to similarly situated companies. The court found that the buyer had failed to carry this burden — the target's performance decline was consistent with the broader industry impact of the pandemic and did not reflect disproportionate harm.

Key Principles. The decision reinforced the importance of the carveout analysis in the MAE framework. Where an adverse development falls squarely within an enumerated carveout, the burden shifts to the buyer to demonstrate disproportionate impact. The court interpreted the pandemic carveout broadly, encompassing not only the direct health effects of COVID-19 but also the secondary economic and operational disruptions attributable to the pandemic and governmental responses thereto.

Relevance to Penterra–Veridian. Snow Phipps illustrates the operation of the pandemic carveout, which is present in the Penterra–Veridian SPA at clause (iv). However, the VRD-4187 clinical data failure and FDA hold are unrelated to any pandemic. There is no factual basis on which the pandemic carveout could be applied to the VRD-4187 events. The decision is useful, however, in confirming that Veridian cannot stretch the pandemic or industry-wide carveouts to cover company-specific clinical trial failures. The carveouts are defined with reference to broadly applicable external forces, not company-specific internal developments.

3. AB Stable VIII LLC v. Maps Hotels & Resorts One LLC (Del. Ch. 2020; affirmed Del. S. Ct. 2021)

AB Stable VIII LLC v. Maps Hotels & Resorts One LLC, C.A. No. 2020-0310-JTL (Del. Ch. Nov. 30, 2020), aff'd, 268 A.3d 198 (Del. 2021), is a significant post-Akorn decision that addressed both the MAE analysis and the ordinary course covenant in the context of the COVID-19 pandemic's impact on the hospitality industry.

Facts. AB Stable VIII LLC ("AB Stable"), an affiliate of Westmark Specialty Insurance, agreed to acquire a portfolio of luxury hotels from Maps Hotels & Resorts One LLC ("Maps Hotels") for approximately $5.8 billion. After signing, the COVID-19 pandemic devastated the hospitality industry. Hotel occupancy rates plummeted, revenues collapsed, and Maps Hotels took drastic operational actions in response — including mass layoffs, property closures, suspension of capital expenditure programs, and entry into government loan programs — all without obtaining the buyer's prior consent as required by the ordinary course covenant. AB Stable sought to terminate the transaction, invoking both the MAE closing condition and the ordinary course covenant.

Holding. Vice Chancellor Slights found that the pandemic-related financ

MEMORANDUM
PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT
TO: Oliver Mackenzie, Partner, Mergers & Acquisitions
FROM: Derek Okonkwo, Associate, Mergers & Acquisitions
DATE: August 27, 2024
RE: Survey of Delaware Material Adverse Effect Case Law — Application to Penterra Pharmaceuticals Corp. / Veridian Biosciences, Inc. Transaction
Matter No.: 1018-00008
Client: Penterra Pharmaceuticals Corp.
Right-click to update Table of Contents
I. Executive Summary and Purpose
This memorandum surveys Delaware Court of Chancery and Delaware Supreme Court jurisprudence on the interpretation and application of material adverse effect ("MAE") provisions in the context of mergers and acquisitions. The memorandum is organized to (a) set forth the governing legal standards that Delaware courts have articulated over the past two decades, (b) analyze each of the principal Delaware decisions addressing MAE claims in detail, and (c) apply the resulting analytical framework to the facts of the Penterra Pharmaceuticals Corp. ("Penterra") and Veridian Biosciences, Inc. ("Veridian") transaction.
This memorandum has been prepared at the request of Oliver Mackenzie in connection with our ongoing analysis of whether the Marlowe Asset Management-2 Phase II clinical trial interim data readout for Veridian's lead candidate, VRD-4187, released on August 14, 2024, and the subsequent partial clinical hold imposed by the U.S. Food and Drug Administration ("FDA") on Investigational New Drug Application No. 154832 (IND 154832), imposed on August 22, 2024, together constitute a "Material Adverse Effect" as that term is defined in Section 1.1 of the Stock Purchase Agreement dated June 10, 2024, by and among Penterra Pharmaceuticals Corp., Veridian Biosciences, Inc., and the Sellers identified therein (the "SPA").
Transaction Overview. Pursuant to the SPA, Penterra agreed to acquire one hundred percent (100%) of the outstanding capital stock of Veridian for an aggregate cash purchase price of $900,000,000 (the "Purchase Price"). The SPA includes a no-MAE closing condition at Section 7.2(b) and a bring-down condition at Section 7.2(a), the latter of which requires that the Sellers' representations and warranties be true and correct as of the Closing Date, qualified in each case to the MAE standard. The Outside Date for the transaction is December 10, 2024.
Key Finding. Delaware courts place an extraordinarily heavy burden on buyers seeking to invoke MAE clauses to avoid closing obligations in acquisition agreements. Prior to 2018, no Delaware court in a reported decision had ever found that a material adverse effect had occurred. However, the 2018 decision in Akorn, Inc. v. Fresenius Kabi AG, issued by Vice Chancellor Laster of the Court of Chancery and subsequently affirmed by the Delaware Supreme Court, established that an MAE finding is not impossible and set forth a comprehensive four-step analytical framework for evaluating MAE claims. When that framework is properly applied to the present facts — the severity and breadth of the adverse clinical safety data, the non-significant efficacy results, the FDA partial clinical hold, and Veridian's status as a clinical-stage company whose enterprise value is principally derived from VRD-4187 — there is a credible basis to support Penterra's position that a Material Adverse Effect has occurred within the meaning of the SPA.
Scope and Limitations. This memorandum is intended to serve as a case law survey and preliminary analytical framework. It is designed to inform the comprehensive, fact-intensive MAE analysis being conducted separately, which will be addressed in a forthcoming memorandum applying the legal standards identified herein to the specific documentary and expert evidence relevant to the Penterra–Veridian transaction. This memorandum does not address in detail the parallel representations bring-down analysis or the ordinary course covenant compliance analysis, each of which will be treated in separate memoranda.
II. Background: The MAE Provision in the Penterra–Veridian SPA
A. Definition of Material Adverse Effect (SPA § 1.1)
Section 1.1 of the SPA defines "Material Adverse Effect" as follows:
"Material Adverse Effect" means any event, change, development, occurrence, condition, or effect that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (a) the business, results of operations, financial condition, or assets of the Company, taken as a whole, or (b) the ability of the Sellers to consummate the Transactions contemplated hereby.
This definition follows the standard two-prong formulation that is prevalent in contemporary acquisition agreements. The first prong — encompassing the business, results of operations, financial condition, or assets of the Company — is the provision most directly implicated by the VRD-4187 clinical data and FDA action. The second prong — addressing the Sellers' ability to consummate the Transactions — is potentially relevant to the extent that the FDA's partial clinical hold or related regulatory developments affect the ability of the Sellers to perform their obligations under the SPA, although our analysis focuses primarily on the first prong.
The definition is both backward-looking ("has had") and forward-looking ("would reasonably be expected to have"). The inclusion of the forward-looking element is significant in the present context. Even if the full financial and commercial effects of the Marlowe Asset Management-2 data and FDA hold have not yet been realized as of the date of this memorandum, the question is whether those events "would reasonably be expected to have" a material adverse effect on Veridian's business, results of operations, financial condition, or assets, taken as a whole. As discussed in Part IV below, Delaware courts applying the forward-looking element of the MAE definition have looked to whether the adverse developments are reasonably expected to be durationally significant and to substantially impair the target's long-term earnings potential or enterprise value.
The phrase "taken as a whole" requires that the MAE analysis be conducted with reference to the Company's entire business, not isolated components thereof. As applied to Veridian, however, this requirement does not diminish the significance of the VRD-4187 events, because Veridian is a clinical-stage company with no revenue, 148 employees, and a pipeline principally centered on VRD-4187 as its lead candidate. For practical purposes, the "taken as a whole" analysis of Veridian converges almost entirely on VRD-4187 and its development prospects.
B. Carveouts
The MAE definition in SPA § 1.1 contains seven enumerated carveouts. Under these carveouts, the following categories of events, changes, developments, occurrences, conditions, or effects are excluded from the determination of whether a Material Adverse Effect has occurred:
(i) changes in general economic or political conditions;
(ii) conditions generally affecting the biotechnology or pharmaceutical industries;
(iii) changes in applicable law or in generally accepted accounting principles ("GAAP") or in the interpretation or enforcement thereof;
(iv) pandemics, epidemics, or disease outbreaks (including COVID-19 and any similar public health emergencies) or any governmental or regulatory responses thereto;
(v) natural disasters, weather events, acts of God, acts of war (whether or not declared), armed hostility, sabotage, or terrorism;
(vi) changes in the financial, banking, or securities markets generally (including any disruption thereof or any changes in prevailing interest rates, exchange rates, or commodity prices); and
(vii) the announcement or pendency of the Transactions contemplated by this Agreement, including the impact thereof on the relationships, contractual or otherwise, of the Company with employees, customers, suppliers, partners, or other third parties.
Carveouts (i) through (vi) are subject to a disproportionate impact exception. Specifically, the SPA provides that the foregoing carveouts shall not apply to the extent that the relevant event, change, or effect disproportionately affects the Company relative to other companies of comparable size and scope operating in the biotechnology industry. This exception preserves the buyer's ability to invoke the MAE clause even where the underlying cause of the adverse event might otherwise fall within a general carveout, provided that the target has been disproportionately affected relative to its industry peers.
Critically, and of particular significance to the present analysis, there is no carveout for company-specific clinical trial results, adverse clinical events, or regulatory actions specific to a company's proprietary products or pipeline candidates. The absence of such a carveout is notable because sophisticated parties negotiating acquisition agreements in the life sciences sector sometimes include carveouts for "the results of clinical trials" or "regulatory actions specific to the Company's products." The negotiating history of the SPA, to the extent it is relevant and admissible, may shed light on whether such a carveout was proposed and rejected. In any event, the absence of such a carveout in the executed SPA means that company-specific clinical trial failures and targeted FDA regulatory actions remain within the scope of the MAE definition.
C. Closing Conditions Implicated
Three closing conditions in the SPA are directly relevant to the MAE analysis:
Section 7.2(a) — Bring-Down of Sellers' Representations and Warranties. This condition requires that the representations and warranties of the Sellers set forth in the SPA shall be true and correct in all respects (or, where qualified by materiality or Material Adverse Effect, in all respects as so qualified) as of the date of the SPA and as of the Closing Date as though made on and as of the Closing Date (except for representations and warranties that address matters only as of a specified date, which need only be true and correct as of such specified date). The bring-down is qualified to the Material Adverse Effect standard — that is, the representations and warranties need not be literally true in every particular, but any inaccuracies must not, individually or in the aggregate, constitute a Material Adverse Effect. Under Akorn, the bring-down condition is analyzed independently from the no-MAE condition described below.
Section 7.2(b) — No Material Adverse Effect. This condition provides that, since the date of the Agreement (June 10, 2024), no Material Adverse Effect shall have occurred that is continuing as of the Closing Date. This is the provision most directly implicated by the VRD-4187 clinical data and FDA hold. The phrase "that is continuing as of the Closing Date" is significant: it provides Veridian with an argument that if the FDA hold were lifted and the clinical program restarted prior to closing, the MAE might not be "continuing." However, as discussed below, even if the hold were lifted, the fundamental impairment to VRD-4187's risk-benefit profile and commercial prospects would persist given the severity of the safety data.
Section 8.1(d) — Buyer's Termination Right. This provision grants the Buyer a right to terminate the SPA if the Buyer's closing conditions set forth in Section 7.2 are incapable of being satisfied by the Outside Date (December 10, 2024), provided that Penterra is not then in material breach of the SPA and that Penterra has provided Veridian with written notice of such failure and the failure has not been cured within thirty (30) days following the date of such notice. Penterra's Deficiency Notice, issued on September 6, 2024, initiates this notice-and-cure period.
D. Factual Context
The following summary of the key factual developments is drawn from the Marlowe Asset Management-2 interim data report, the FDA correspondence, and other materials made available to this firm. A more detailed factual analysis will be contained in the forthcoming comprehensive MAE memorandum.
Marlowe Asset Management-2 Phase II Interim Data (August 14, 2024). On August 14, 2024, the Data Monitoring Committee ("DMC") for the Marlowe Asset Management-2 Phase II clinical trial conducted a pre-specified interim analysis. The results revealed the following:
• Safety: The treatment arm exhibited a 23.4% incidence of Grade 3 or higher cytokine release syndrome ("CRS"), compared to 4.1% in the control arm. There were seven (7) treatment-related deaths in the treatment arm (3.6% of enrolled patients) compared to one (1) death in the control arm (0.5%).
• Efficacy: The overall response rate ("ORR") was 31.4% in the treatment arm compared to 28.9% in the control arm, with a p-value of 0.58. This result is not statistically significant, meaning the data did not demonstrate a meaningful efficacy advantage for VRD-4187 over the standard of care comparator.
In combination, the data indicate that VRD-4187 in its current formulation and dosing regimen demonstrates no statistically significant efficacy benefit while carrying a dramatically elevated safety risk — a risk-benefit profile that, on its face, is inconsistent with an approvable New Drug Application ("NDA") pathway.
FDA Partial Clinical Hold (August 22, 2024). On August 22, 2024, the FDA imposed a partial clinical hold on IND 154832 covering the Marlowe Asset Management-2 trial. A partial clinical hold suspends some but not all clinical work under the IND; in this case, new enrollment in the Marlowe Asset Management-2 trial has been halted pending FDA review of the safety data and Veridian's response. The partial clinical hold has no predetermined end date; its resolution requires Veridian to submit a complete response to the FDA's clinical hold letter addressing the identified safety concerns, after which the FDA will have thirty (30) days to review and either lift the hold or request additional information.
Veridian's Status as a Clinical-Stage Company. Veridian is a clinical-stage biopharmaceutical company with zero revenue for fiscal year 2023 (and all prior periods), approximately 148 employees, and a pipeline principally centered on VRD-4187 as its lead and most advanced therapeutic candidate. Veridian has raised approximately $420 million in total venture capital financing. The $900 million acquisition price negotiated by the parties was predicated principally on the expected commercial value of VRD-4187 and its anticipated regulatory and market prospects.
Procedural History. On September 6, 2024, Penterra delivered a Deficiency Notice to Veridian identifying the Marlowe Asset Management-2 interim data and FDA partial clinical hold as constituting a Material Adverse Effect under the SPA and asserting that the closing conditions in Sections 7.2(a) and 7.2(b) were not capable of being satisfied. On September 13, 2024, Veridian delivered a written response disputing that a Material Adverse Effect had occurred and contending that the clinical data are preliminary and subject to remediation through its ongoing protocol amendments.
III. The Legal Standard for Material Adverse Effect Under Delaware Law
A. General Principles
Material adverse effect clauses are among the most significant risk-allocation mechanisms in acquisition agreements. They operate principally in two contexts: (1) as a qualification to representations and warranties, limiting the scope of those representations to matters that are material to the target's business; and (2) as a closing condition, permitting the buyer to refuse to close the transaction if an MAE has occurred between signing and closing. The present analysis focuses primarily on the second context — the no-MAE closing condition — although the representations bring-down analysis (which itself is qualified to the MAE standard) is also implicated, as discussed in Part II.C above.
Delaware courts interpret MAE clauses according to their plain language, giving effect to the parties' contractual allocation of risk as expressed in the text of the agreement. Where the contractual language is unambiguous, the court applies that language in accordance with its ordinary meaning, informed by the commercial context in which the agreement was negotiated and executed. As Vice Chancellor Strine observed in the foundational IBP decision, the purpose of an MAE clause is "to protect the acquiror from the occurrence of unknown events that substantially threaten the overall earnings potential of the target in a durationally-significant manner." In re IBP, Inc. S'holders Litig., 789 A.2d 14, 68 (Del. Ch. 2001).
The buyer bears the burden of proving that a material adverse effect has occurred. This allocation of the burden of proof is well-established in Delaware jurisprudence and reflects the policy judgment that the MAE standard is designed as a backstop against unexpected and severe adverse developments, not as a general exit mechanism for buyers experiencing doubts about a transaction. The buyer must demonstrate, by a preponderance of the evidence, that the facts satisfy each element of the contractual MAE definition.
The standard for determining whether an event or development constitutes an MAE is qualitative and contextual. Delaware courts have consistently declined to adopt a bright-line percentage test or numerical threshold for materiality in the MAE context. Instead, the analysis requires a holistic assessment of the nature, severity, duration, and reversibility of the adverse development, viewed in the context of the target company's overall business and the reasonable expectations of the parties at the time of signing. This contextual approach necessarily means that the significance of a given adverse development will vary depending on the nature of the target's business, its industry, its financial profile, and the specific circumstances of the transaction.
Courts have historically recognized that the MAE standard is designed to protect buyers against adverse developments that are consequential to the long-term value of the target, not against short-term or transient fluctuations in performance. This principle — the "durational significance" requirement — is the single most important analytical tool in the Delaware MAE framework and is discussed in greater detail in Part III.B below.
B. Durational Significance
The concept of durational significance is the central pillar of Delaware MAE jurisprudence. First articulated by Vice Chancellor Strine in IBP, the principle holds that an adverse effect must be "durationally significant" in order to constitute a material adverse effect — that is, it must substantially threaten the overall earnings potential of the target in a manner that is significant when measured not in terms of short-term results but rather from the longer-term perspective of a reasonable acquiror.
The durational significance standard serves a critical gatekeeping function. It distinguishes between, on the one hand, temporary setbacks, cyclical downturns, or transient market fluctuations that a reasonable buyer would expect to encounter and weather over the course of owning the target business, and, on the other hand, fundamentally value-destructive events that permanently or semi-permanently impair the target's ability to generate earnings or achieve its expected commercial potential.
The concept evolved through several cases in the years following IBP. In Hexion Specialty Chemicals, Inc. v. Huntsman Corp., 965 A.2d 715 (Del. Ch. 2008), the court applied the durational significance standard in the context of a financial downturn, concluding that the target's declining performance was attributable to macroeconomic conditions that did not warrant an MAE finding. In Akorn, Inc. v. Fresenius Kabi AG, C.A. No. 2018-0300-JTL (Del. Ch. Oct. 1, 2018), aff'd, 198 A.3d 724 (Del. 2018), Vice Chancellor Laster reaffirmed and refined the standard, finding that the target's approximately 86% decline in EBITDA sustained over multiple quarters, combined with pervasive regulatory violations that impaired its future operating capacity, was "durationally significant" in a manner that no reasonable acquiror could dismiss as temporary.
Courts assess durational significance by looking to the long-term horizon of the reasonable buyer — typically measured in years rather than months. A decline in a single quarter's earnings, even a substantial one, is generally insufficient to satisfy the durational significance standard if the decline is attributable to temporary or cyclical factors. Conversely, an adverse development that permanently impairs a core asset or capability of the target — such as the loss of a key regulatory approval, the permanent shutdown of a critical manufacturing facility, or, as in Akorn, the discovery of pervasive data integrity violations — is more likely to be found durationally significant because its effects will persist indefinitely.
The durational significance standard presents particular analytical challenges in the context of clinical-stage companies. For a target with no revenue and no current earnings, the concept of a "decline in earnings potential" must be adapted to focus on the impairment of expected future value derived from the company's pipeline. Where the target's enterprise value is derived principally from a single clinical program — as is the case with Veridian and VRD-4187 — a severe adverse clinical event that fundamentally impairs the lead candidate's development prospects can be analogized to a devastating and sustained decline in earnings for a revenue-generating company.
C. The "Reasonable Acquiror" Standard
The MAE analysis is conducted from an objective standpoint: the question is whether a reasonable acquiror would view the adverse development as materially altering the value proposition of the target. The buyer's subjective motivations — including so-called "buyer's remorse" — are irrelevant. See Hexion, 965 A.2d at 738 (rejecting buyer's MAE claim in part because of evidence that the buyer was seeking to escape the transaction for reasons unrelated to the target's performance).
The reasonable acquiror standard is not measured solely by reference to short-term financial results. Rather, the hypothetical reasonable acquiror is assumed to be a sophisticated market participant purchasing the long-term earnings potential of the target business. This acquiror is presumed to understand the industry dynamics, business cycles, and inherent risks associated with the target's business, and to have priced those known risks into the transaction at signing. The MAE clause protects against unknown or unforeseen developments that materially alter the value that the reasonable acquiror expected to receive.
The target is evaluated "as a whole" — not in isolation by individual products, assets, or business segments. For a diversified company with multiple revenue streams, an adverse event affecting one product line might not constitute an MAE if the company's other businesses remain healthy. However, for a single-product or clinical-stage company such as Veridian, the lead asset may effectively be the whole company. In such circumstances, the "taken as a whole" qualifier does not provide meaningful insulation, because an adverse event affecting the lead asset necessarily affects the company as a whole.
D. Magnitude of the Adverse Change
Delaware courts have declined to establish a fixed numerical threshold for the magnitude of adverse change required to constitute an MAE. The analysis depends on the totality of the circumstances, including the nature of the adverse development, the target's business and financial profile, the industry context, and the parties' reasonable expectations at signing.
That said, the case law provides some guideposts. In IBP, Vice Chancellor Strine noted that the buyer's expert suggested a decline of approximately 40% or more in earnings might constitute an MAE, and the court appeared to treat that range as a reasonable benchmark — while emphasizing that it was not adopting a rigid standard. 789 A.2d at 67. In Akorn, the approximately 86% decline in EBITDA was, in the court's view, clearly sufficient to meet the magnitude requirement, even standing alone. The court noted that a decline of that magnitude was "many times greater" than the thresholds that practitioners and commentators have discussed as potentially material. Akorn, C.A. No. 2018-0300-JTL, at *166.
For clinical-stage biotechnology companies with no revenue, the traditional earnings-based metrics used to measure the magnitude of adverse change are inapplicable. There are no historical earnings, EBITDA, or revenue figures against which to calculate a percentage decline. Instead, the analysis must focus on the impairment of expected future value derived from the pipeline. This may require resort to discounted cash flow analyses, comparable transaction valuations, probability-weighted pipeline valuations, or other methodologies that can quantify the extent to which the adverse clinical events have reduced the expected commercial value of the target's pipeline assets — and, by extension, the enterprise value of the company. The translation of these analytical tools into the MAE framework for clinical-stage companies is an area of limited Delaware authority, as discussed further in Part IV.D below.
IV. Key Delaware Cases
This Part surveys the principal Delaware decisions addressing MAE claims in acquisition transactions. The cases are organized chronologically and thematically: pre-Akorn jurisprudence (establishing the high standard for MAE claims), the Akorn decision (the watershed moment), and post-Akorn jurisprudence (applying and refining the Akorn framework).
A. Pre-Akorn Jurisprudence: The Historical Reluctance to Find MAE
1. In re IBP, Inc. Shareholders Litigation (Del. Ch. 2001)
In re IBP, Inc. Shareholders Litigation, 789 A.2d 14 (Del. Ch. 2001), is the foundational Delaware decision on MAE analysis and remains one of the most frequently cited opinions in this area.
Facts. Fenmore Partners LLC ("Tyson") agreed to acquire IBP, Inc. ("IBP"), a major meat processing company, in a transaction valued at approximately $3.2 billion. After signing the merger agreement, IBP reported significant earnings declines in the fourth quarter of 2000 and the first quarter of 2001. IBP's earnings in Q4 2000 were approximately 64% lower than the prior year's comparable quarter. In addition, accounting irregularities were discovered at DFG Foods, an IBP subsidiary, involving improper revenue recognition. Tyson sought to invoke the MAE clause in the merger agreement and to terminate the transaction, arguing that the combination of the earnings decline and the accounting irregularities constituted a material adverse effect.
Holding. Vice Chancellor Strine held that no material adverse effect had occurred. The court found that the earnings decline, while significant on a quarter-over-quarter basis, was not durationally significant because IBP's business was inherently cyclical and seasonal. The meat processing industry was subject to well-known fluctuations driven by livestock supply cycles, commodity pricing, and weather patterns. A reasonable acquiror with knowledge of IBP's business would have understood these cyclical dynamics at the time of signing and would not have viewed a single-quarter downturn — even a severe one — as a fundamental impairment of IBP's long-term earnings potential. As to the DFG Foods accounting irregularities, the court found that the issues were confined to a subsidiary that represented a small fraction of IBP's overall business and did not rise to the level of materiality when viewed in the context of the company "as a whole."
The court also found that Tyson's real motivation was buyer's remorse — Tyson had grown concerned about its own financial capacity and strategic direction and was using the MAE clause as a pretext to exit a deal it no longer wanted. While the court noted that the buyer's subjective motivations are not directly relevant to the objective MAE analysis, Tyson's conduct undercut the credibility of its factual assertions and reinforced the court's skepticism of the MAE claim.
Key Principles Established.
Durational Significance. The IBP decision introduced the "durational significance" standard that has become the cornerstone of Delaware MAE jurisprudence. Vice Chancellor Strine held that "short-term hiccups in earnings should not suffice" to establish an MAE, because "acquirors [are] purchasing the long-term value of the business." 789 A.2d at 68. An MAE must be measured against the long-term value of the target, not against quarterly or annual fluctuations.
High Bar. The decision set a very high bar for establishing an MAE. The court's refusal to find an MAE despite a 64% quarterly earnings decline signaled to practitioners and courts alike that the threshold for an MAE finding was significantly higher than many had previously assumed.
Cyclical Risk. A reasonable acquiror is presumed to have understood the cyclical risks inherent in the target's industry at the time of signing. A downturn consistent with known cyclical patterns does not constitute an MAE.
Taken as a Whole. The adverse developments must be material to the company "as a whole," not merely to isolated segments or subsidiaries.
Relevance to Penterra–Veridian. The IBP decision is distinguishable from the Penterra–Veridian facts in several critical respects. First, IBP was a mature, revenue-generating company with a long operating history and well-understood cyclical patterns. The court's conclusion that the earnings decline was not durationally significant rested heavily on the cyclical nature of the meat processing industry — a reasonable acquiror understood that earnings would fluctuate over time and priced that volatility into the deal. Veridian, by contrast, is a clinical-stage company with $0 revenue. The VRD-4187 clinical data failure is not a "cyclical" event that a reasonable acquiror would have anticipated as part of the normal ebb and flow of the business; it is a discrete, potentially permanent impairment of the company's lead — and effectively sole — value driver.
Second, and relatedly, the IBP court's analysis focused on the target's historical financial performance and the expectation that earnings would revert to the mean over time. In the Veridian context, there is no historical earnings pattern to which the business can be expected to revert. The value of Veridian is entirely forward-looking, derived from the anticipated commercial success of VRD-4187. An adverse development that fundamentally impairs VRD-4187's development prospects does not present the same "cyclical reversion" dynamic that saved IBP.
Third, the DFG Foods accounting issues in IBP were isolated to a small subsidiary. Here, the adverse events go to the core of Veridian's only advanced clinical program and affect the single compound that constitutes substantially all of the company's enterprise value.
2. Frontier Oil Corp. v. Holly Corp. (Del. Ch. 2005)
Frontier Oil Corp. v. Holly Corp., 2005 WL 1039027 (Del. Ch. Apr. 29, 2005), provided additional guidance on the buyer's burden in establishing an MAE.
Facts. Holly Corporation ("Holly") entered into a merger agreement with Frontier Oil Corporation ("Frontier"). After signing, Frontier sought to argue that certain environmental liabilities at Holly's operations, combined with a pending SEC investigation into Holly's financial reporting practices, constituted a material adverse effect that excused Frontier from its closing obligations.
Holding. The Court of Chancery declined to find that an MAE had occurred. The court emphasized that the buyer had failed to carry its burden of demonstrating that the identified developments substantially threatened the target's long-term earnings potential. The environmental liabilities, while potentially costly, were of a type common to companies in the refining industry and had not been shown to be of a magnitude that would fundamentally impair Holly's ability to operate its business over the long term. The SEC investigation, while creating uncertainty, had not resulted in any enforcement action or restatement at the time of the decision, and the court was unwilling to treat speculative future regulatory outcomes as a present MAE.
Key Principle. The buyer must demonstrate materiality in the context of the overall enterprise, not in isolation by reference to individual liabilities, contingencies, or regulatory proceedings. A pending investigation or potential liability, without more, is generally insufficient to establish an MAE where the ultimate outcome and magnitude of the exposure remain uncertain.
Relevance to Penterra–Veridian. Frontier Oil reinforces the high burden faced by buyers invoking MAE clauses, but it is distinguishable on the facts. The environmental and SEC issues in Frontier Oil were contingent and speculative — their ultimate impact on Holly's business was uncertain. By contrast, the VRD-4187 clinical data is not speculative; it consists of actual, quantified safety and efficacy results from a controlled clinical trial, and the FDA partial clinical hold is a concrete regulatory action that has already halted enrollment in the Marlowe Asset Management-2 trial. The adverse developments here are not merely potential — they have already materialized.
3. Hexion Specialty Chemicals, Inc. v. Huntsman Corp. (Del. Ch. 2008)
Hexion Specialty Chemicals, Inc. v. Huntsman Corp., 965 A.2d 715 (Del. Ch. 2008), addressed MAE claims arising in the context of the 2008 financial crisis and provided important guidance on the operation of carveouts and the disproportionate impact exception.
Facts. Hexion Specialty Chemicals, Inc. ("Hexion"), a portfolio company of Ridgeline Investors, agreed to acquire Brundavel Corporation ("Huntsman"), a diversified chemical company, in a leveraged buyout valued at approximately $10.6 billion. After signing, the global financial crisis of 2008 caused significant disruption across the chemical industry, and Huntsman's financial performance declined materially. Hexion sought a declaratory judgment that it was not obligated to close the transaction, arguing that Huntsman had suffered an MAE and that the combined entity would be insolvent.
Holding. Vice Chancellor Lamb found that no MAE had occurred. The court concluded that Huntsman's financial decline was largely attributable to the general economic downturn and conditions affecting the chemical industry broadly — both of which fell within the carveout provisions of the merger agreement. Because the adverse effects were attributable to carved-out causes, they could not form the basis of an MAE finding unless Hexion demonstrated that Huntsman had been disproportionately affected relative to other companies in the chemical industry. The court found that Hexion had failed to carry this burden; Huntsman's performance decline was consistent with the industry-wide downturn and did not reflect disproportionate impact.
The court further found that Hexion had acted in bad faith by commissioning a solvency opinion designed to create a pretext for termination. While this finding did not directly affect the MAE analysis (which is objective), it contributed to the court's overall assessment of the equities and reinforced the principle that a buyer cannot manufacture grounds for termination.
Key Principles.
Operation of Carveouts. Industry-wide and macroeconomic downturns typically fall within the enumerated carveouts found in most MAE definitions. When the adverse effects are attributable to carved-out causes, they are excluded from the MAE analysis unless the disproportionate impact exception applies.
Disproportionate Impact Analysis. Even when a general carveout applies, the buyer may reinstate the MAE by demonstrating that the target was disproportionately affected relative to comparably situated companies. This requires a comparative analysis showing that the target's performance deteriorated more severely than that of its industry peers during the same period.
Subjective Motivations Irrelevant. The buyer's subjective motivations — including buyer's remorse, strategic shifts, or financing difficulties — are irrelevant to the objective MAE analysis. However, evidence of bad faith may inform the court's assessment of the buyer's credibility and the equities of the case.
Relevance to Penterra–Veridian. Hexion is significant to the Penterra–Veridian analysis principally for its treatment of carveouts and the disproportionate impact exception. The SPA in the present transaction contains similar carveout provisions, including carveouts for general economic conditions and conditions affecting the biotechnology or pharmaceutical industries generally. However, unlike the financial crisis at issue in Hexion, the VRD-4187 clinical data failure and FDA hold are company-specific events. They are not attributable to general economic conditions, industry-wide trends, or macroeconomic disruptions. Accordingly, the carveout analysis should not present a barrier to Penterra's MAE claim. To the extent Veridian attempts to invoke the industry-wide carveout — arguing, for example, that clinical trial failures are an inherent risk of the biotechnology industry — the disproportionate impact exception would reinstate the MAE, as the VRD-4187 events are specific to Veridian's proprietary compound and clinical program.
4. Additional Pre-Akorn Cases
Several additional pre-Akorn decisions further illustrate the pattern of buyer difficulty in establishing MAE claims under Delaware law. While a comprehensive treatment of each is beyond the scope of this memorandum, the following brief summaries are instructive:
Genworth Financial, Inc. v. AGL Resources, Inc. In this matter, the parties disputed whether certain adverse regulatory developments constituted an MAE under the merger agreement. Consistent with the broader pattern, the court declined to find an MAE, emphasizing the high burden on the buyer and the target's continued operational viability notwithstanding the regulatory challenges.
Other Decisions. In the period between IBP (2001) and Akorn (2018), no Delaware court in a reported decision found that a material adverse effect had occurred. This seventeen-year streak of buyer defeats created a perception — widespread among practitioners — that the MAE clause was essentially a "dead letter" provision that existed in merger agreements as a matter of drafting convention but could never realistically be invoked. The Akorn decision would prove that perception wrong.
The significance of this unbroken record of seller victories cannot be overstated. It means that any buyer invoking an MAE clause in Delaware faces not only the formal legal burden of proof but also the practical burden of overcoming a strong judicial presumption — born of historical experience — that MAE claims are disfavored. Penterra must be prepared to demonstrate that the present facts are truly exceptional, on the order of Akorn itself.
B. The Akorn Decision: The Watershed Moment
1. Akorn, Inc. v. Fresenius Kabi AG (Del. Ch. 2018; affirmed Del. S. Ct. 2018)
Akorn, Inc. v. Fresenius Kabi AG, C.A. No. 2018-0300-JTL, 2018 WL 4719347 (Del. Ch. Oct. 1, 2018), aff'd, 198 A.3d 724 (Del. 2018), is the most important Delaware decision on MAE law and provides the governing analytical framework for evaluating MAE claims in post-signing disputes.
Facts in Detail. In April 2017, Fresenius Kabi AG ("Fresenius"), a global healthcare company, agreed to acquire Akorn, Inc. ("Akorn"), a specialty generic pharmaceutical company, for approximately $4.75 billion in a reverse triangular merger. The merger agreement contained a standard MAE clause with customary carveouts and closing conditions.
After signing, Akorn experienced a catastrophic deterioration on two fronts. First, Akorn's financial performance collapsed. In the quarters following the signing of the merger agreement, Akorn's year-over-year EBITDA declined by approximately 86%, and revenues dropped by approximately 25% to 34% depending on the measurement period. These declines were sustained over multiple consecutive quarters and were not attributable to seasonal or cyclical factors. Akorn's management attributed the decline to increased generic drug competition, pricing pressure, and the loss of certain product approvals, but the magnitude of the decline far exceeded anything reasonably foreseeable at the time of signing.
Second, and independently, extensive FDA data integrity violations were discovered at multiple Akorn manufacturing facilities. Whistleblower reports led Fresenius to commission an investigation, which uncovered pervasive problems with Akorn's quality assurance and regulatory compliance systems. The investigation revealed that Akorn employees had systematically falsified data submitted to the FDA in connection with abbreviated New Drug Applications ("ANDAs"), including fabricating test results, backdating stability data, and manipulating product testing protocols. The violations were not isolated to a single facility or a small group of employees; they were systemic and affected multiple sites and product lines. The FDA data integrity issues went to the core of Akorn's ability to manufacture and sell generic pharmaceutical products — activities that constituted Akorn's entire business model.
Fresenius notified Akorn that it believed a material adverse effect had occurred and that it intended to terminate the merger agreement. Akorn filed suit seeking specific performance of the merger. The Court of Chancery conducted a five-day trial.
Holding. In a comprehensive 246-page opinion, Vice Chancellor Laster held that a material adverse effect had occurred — the first reported Delaware decision to so hold. The court found that the closing conditions in the merger agreement were not satisfied, and that Fresenius was entitled to terminate the transaction. The Delaware Supreme Court affirmed on December 7, 2018, in a brief opinion endorsing the Court of Chancery's reasoning and conclusions.
Key Principles and Analytical Framework. The Akorn decision established a comprehensive four-step framework for evaluating MAE claims under Delaware law, together with detailed guidance on each step.
(a) The Four-Step MAE Analysis. Vice Chancellor Laster organized the MAE analysis into four sequential inquiries:
Step 1: Has a Material Adverse Effect occurred within the meaning of the contractual definition? This requires application of the durational significance standard, considering both quantitative and qualitative factors.
Step 2: Does the MAE fall within one of the contractual carveouts or exceptions? If so, the effect is excluded from the MAE analysis (subject to Step 3).
Step 3: If a carveout applies, does the disproportionate impact exception reinstate the MAE? The buyer must show that the target was disproportionately affected relative to comparably situated companies.
Step 4: Did the buyer contribute to or cause the MAE such that it should be equitably estopped from invoking the MAE clause? This inquiry addresses whether the buyer's own conduct caused or materially contributed to the adverse developments.
This four-step framework has become the standard analytical structure for MAE claims in Delaware and is the framework that should be applied to the Penterra–Veridian facts.
(b) Quantitative and Qualitative Factors (Step 1). In applying the first step of the analysis, the court considered both quantitative financial metrics and qualitative operational factors.
On the quantitative side, the court found that Akorn's approximately 86% decline in EBITDA over multiple quarters was "overwhelming" and satisfied even the most stringent interpretation of the durational significance standard. The court observed that this decline was "many times greater" than the thresholds discussed by commentators and that no reasonable acquiror could view such a decline as a temporary blip. The court also noted that the decline was sustained — it persisted over multiple consecutive quarters with no indication of reversal — and was expected to continue indefinitely based on the competitive dynamics facing Akorn's product portfolio.
On the qualitative side, the court found that the pervasive FDA data integrity violations independently constituted a development of MAE magnitude. The violations went to the core of Akorn's ability to maintain its FDA-approved manufacturing operations and to market its products. The court emphasized that for a generic pharmaceutical company whose entire business model depended on regulatory compliance, the discovery of systematic data falsification was not merely a quantitative financial setback but a qualitative impairment of the company's fundamental operating capacity. The regulatory violations created a "cloud" over Akorn's business that would persist for years, impairing its ability to obtain new product approvals, retain existing approvals, and maintain its relationships with customers and regulators.
The court's treatment of qualitative factors is particularly relevant to the Penterra–Veridian analysis, where the adverse clinical data and FDA hold represent qualitative impairments to VRD-4187's development program that cannot be fully captured by traditional financial metrics.
(c) Representations Bring-Down (Analyzed Separately from MAE). Vice Chancellor Laster separately analyzed the representations bring-down condition in the merger agreement. This analysis was independent of the MAE closing condition analysis; the court found that the bring-down condition was not satisfied for reasons that partially overlapped with, but were distinct from, the MAE finding.
Specifically, the court found that Akorn's representations regarding its regulatory compliance — including representations that it had complied in all material respects with applicable FDA regulations — were inaccurate in all material respects at the time of closing. The data integrity violations rendered these representations false, and the inaccuracies were of a magnitude that constituted a Material Adverse Effect when measured against the bring-down standard.
This aspect of the Akorn decision is significant because it establishes that the no-MAE closing condition and the representations bring-down condition are independent bases for non-satisfaction of closing conditions. A buyer pursuing an MAE-related defense should assert both grounds wherever the facts support them, as Penterra has done in its Deficiency Notice.
(d) The Ordinary Course Covenant. The Akorn court also found that Akorn had breached its obligation to operate the business in the ordinary course between signing and closing. This finding provided an additional, independent ground for Fresenius to refuse to close. While the ordinary course covenant analysis is not central to this MAE case law survey, it is worth noting that the Akorn decision reinforces the principle that multiple closing conditions should be evaluated independently, as any one of them may independently support the buyer's refusal to close.
Relevance to Penterra–Veridian. Akorn is the leading precedent and the only reported Delaware case in which a court found an MAE. It provides the governing analytical framework that will be applied to the Penterra–Veridian facts. Several aspects of the comparison merit particular attention.
Distinguishing Factors. The most significant distinction between Akorn and the present case is that Akorn was a revenue-generating company with historical financial results against which the magnitude of adverse change could be directly measured. The approximately 86% decline in EBITDA was a striking, easily quantifiable figure that left no doubt about the severity of the impact. Veridian, by contrast, has $0 in revenue and no historical earnings. There is no EBITDA to decline. The quantitative analysis must therefore be conducted by reference to the impairment of expected future value — the reduction in the probability-weighted net present value of VRD-4187's commercial potential — rather than historical financial performance. This is a more complex and contested analysis, and the absence of a concrete, easily calculable percentage decline may make it harder for Penterra to establish the same degree of quantitative certainty that the Akorn court found.
Analogous Factors. Notwithstanding the foregoing distinction, several aspects of the Akorn facts are strongly analogous to the present case:
• Regulatory impairment at the core of the business. Just as the FDA data integrity violations in Akorn went to the core of Akorn's ability to manufacture and sell generic pharmaceuticals — i.e., the company's entire business — the FDA partial clinical hold on VRD-4187 goes to the core of Veridian's ability to develop and commercialize its lead product. VRD-4187 is the primary value driver in a $900 million transaction.
• Pervasiveness and systemic nature of the problems. The Akorn court emphasized the pervasive, systemic nature of the data integrity violations — they were not isolated to a single facility or product but affected multiple sites and product lines. Similarly, the VRD-4187 safety signal is not an isolated adverse event but a systemic finding across the treatment arm: 23.4% of patients experienced Grade 3 or higher CRS, and 3.6% of treatment-arm patients died. The breadth of the safety signal suggests a fundamental problem with the compound's mechanism of action or dosing, not a random or isolated occurrence.
• Single-asset dependency. While Akorn had multiple products, the court noted that the data integrity violations affected the company's ability to operate its core business. Veridian's dependency on VRD-4187 is, if anything, even more extreme — VRD-4187 is the lead candidate and the principal (if not sole) basis for the $900 million valuation. The impairment of VRD-4187 thus impairs substantially all of Veridian's enterprise value.
• Expected indefinite duration. The Akorn court found that the adverse effects were expected to persist indefinitely. Here, the FDA partial clinical hold has no fixed end date, and even if lifted, VRD-4187 would need to restart with a modified protocol, re-enroll patients, and generate entirely new safety and efficacy data — a process that would take multiple years and whose outcome is uncertain.
2. Delaware Supreme Court Affirmance of Akorn
The Delaware Supreme Court affirmed the Court of Chancery's decision in Akorn on December 7, 2018, in a relatively brief opinion. Akorn, Inc. v. Fresenius Kabi AG, 198 A.3d 724 (Del. 2018). The Supreme Court endorsed the Vice Chancellor's multi-factor analytical approach without significant modification. The court confirmed that MAE findings, while rare, are available when the underlying facts are sufficiently severe. The Supreme Court observed that the burden on the buyer remains "heavy" but is "not insurmountable," and that the trial court had properly applied the durational significance standard and the other elements of the MAE framework to the particular facts of the case.
The Supreme Court's affirmance is significant for two reasons. First, it establishes that the four-step analytical framework articulated by Vice Chancellor Laster is the governing standard for MAE claims in Delaware — it has the imprimatur of the state's highest court, not merely the Court of Chancery. Second, the Supreme Court's characterization of the buyer's burden as "heavy" but "not insurmountable" provides a useful counterpoint to the pre-Akorn perception that MAE claims were effectively impossible to prove. The Supreme Court's language signals that courts should take MAE claims seriously when the facts warrant, even if the standard remains demanding.
C. Post-Akorn Jurisprudence
1. Channel Medsystems, Inc. v. Boston Scientific Corp. (Del. Ch. 2019)
Channel Medsystems, Inc. v. Boston Scientific Corp., C.A. No. 2018-0673-AGB (Del. Ch. 2019), is a particularly significant post-Akorn decision for the Penterra–Veridian analysis because it addressed MAE claims arising from adverse clinical events in the healthcare context.
Facts. Greaves Corporation ("Boston Scientific") entered into an agreement to acquire Channel Medsystems, Inc. ("Channel"), a medical device company. After signing, a patient death occurred during a clinical trial of Channel's lead product. The FDA initiated an investigation into the circumstances of the death, and the clinical trial was suspended. Boston Scientific invoked the MAE clause in the acquisition agreement, arguing that the patient death and FDA investigation constituted a material adverse effect that excused it from closing.
Holding. The Court of Chancery found that a single adverse clinical event, while serious, did not constitute an MAE where the issue was potentially remediable and the company had other pipeline assets that contributed to its overall value. The court emphasized that the patient death, while tragic, was an isolated event that did not reflect a systemic safety problem with the product. The FDA investigation was ongoing and could potentially be resolved without permanent impairment to the product's regulatory pathway. Moreover, Channel had other products and pipeline candidates that contributed to its enterprise value, meaning that the adverse event affecting one product did not necessarily impair the company "taken as a whole."
Key Principle. Isolated clinical events may not rise to the level of MAE unless they fundamentally impair the target's long-term value. Remediability is a relevant factor — if the adverse event can reasonably be expected to be remediated through protocol modifications, additional clinical work, or other corrective measures, it is less likely to be found durationally significant.
Relevance to Penterra–Veridian. Channel Medsystems provides both favorable and unfavorable elements for Penterra's position.
Unfavorable elements: The decision establishes that adverse clinical events — including patient deaths and FDA investigations — do not automatically constitute MAE, and that remediability is a factor weighing against an MAE finding. Veridian will undoubtedly cite Channel Medsystems for the proposition that clinical setbacks are inherent to the development of novel therapeutics and that the VRD-4187 safety issues can be addressed through protocol modifications (as evidenced by Veridian's Protocol v4.0 amendment).
Favorable elements — distinguishing features: The VRD-4187 situation is materially distinguishable from Channel Medsystems in several critical respects:
• The VRD-4187 safety signal is not an isolated event involving a single patient. It is a systemic finding across the entire treatment arm: 23.4% of patients experienced Grade 3 or higher CRS, and 7 patients (3.6%) died. This is a fundamentally different situation from a single patient death.
• The VRD-4187 efficacy data is non-significant (ORR 31.4% vs. 28.9%, p = 0.58), meaning the drug failed to demonstrate an efficacy advantage over standard of care. In Channel Medsystems, the safety event was the sole problem; there was no simultaneous efficacy failure. The combination of elevated safety risk and non-significant efficacy creates a compounded problem that is far more severe.
• Channel had other pipeline assets that contributed to its enterprise value, diluting the impact of the adverse event on the company "taken as a whole." Veridian is a clinical-stage company with no revenue and no other advanced pipeline candidates. VRD-4187 is essentially the entirety of the company's value proposition.
• The remediability analysis is more problematic for VRD-4187 than for the Channel product. Even if Veridian modifies the protocol (as it has done with Protocol v4.0, reducing the dose from 1.5 mg/kg to 0.75 mg/kg and adding mandatory tocilizumab prophylaxis), the modified regimen has not been clinically validated. The dose reduction may eliminate the already non-significant efficacy signal. Remediability in this context is speculative and would require years of additional clinical development with uncertain outcomes.
2. Snow Phipps Group, LLC v. KCake Acquisition, Inc. (Del. Ch. 2021)
Snow Phipps Grp., LLC v. KCake Acquisition, Inc., C.A. No. 2020-0282-KSJM (Del. Ch. Apr. 30, 2021), addressed MAE claims arising from the COVID-19 pandemic's impact on a retail food service business.
Facts. Snow Phipps Group, LLC ("Snow Phipps") sought to invoke the MAE clause in a stock purchase agreement to avoid closing its acquisition of a restaurant and bakery business after the COVID-19 pandemic caused dramatic declines in the target's revenues and operations. The target's business was severely affected by government-mandated shutdowns, reduced consumer traffic, and operational disruptions.
Holding. The Court of Chancery found that no MAE had occurred. The court held that the pandemic-related disruptions fell squarely within the pandemic carveout contained in the MAE definition. Because the adverse effects were attributable to a carved-out cause, they could not constitute an MAE unless the buyer demonstrated disproportionate impact relative to similarly situated companies. The court found that the buyer had failed to carry this burden — the target's performance decline was consistent with the broader industry impact of the pandemic and did not reflect disproportionate harm.
Key Principles. The decision reinforced the importance of the carveout analysis in the MAE framework. Where an adverse development falls squarely within an enumerated carveout, the burden shifts to the buyer to demonstrate disproportionate impact. The court interpreted the pandemic carveout broadly, encompassing not only the direct health effects of COVID-19 but also the secondary economic and operational disruptions attributable to the pandemic and governmental responses thereto.
Relevance to Penterra–Veridian. Snow Phipps illustrates the operation of the pandemic carveout, which is present in the Penterra–Veridian SPA at clause (iv). However, the VRD-4187 clinical data failure and FDA hold are unrelated to any pandemic. There is no factual basis on which the pandemic carveout could be applied to the VRD-4187 events. The decision is useful, however, in confirming that Veridian cannot stretch the pandemic or industry-wide carveouts to cover company-specific clinical trial failures. The carveouts are defined with reference to broadly applicable external forces, not company-specific internal developments.
3. AB Stable VIII LLC v. Maps Hotels & Resorts One LLC (Del. Ch. 2020; affirmed Del. S. Ct. 2021)
AB Stable VIII LLC v. Maps Hotels & Resorts One LLC, C.A. No. 2020-0310-JTL (Del. Ch. Nov. 30, 2020), aff'd, 268 A.3d 198 (Del. 2021), is a significant post-Akorn decision that addressed both the MAE analysis and the ordinary course covenant in the context of the COVID-19 pandemic's impact on the hospitality industry.
Facts. AB Stable VIII LLC ("AB Stable"), an affiliate of Westmark Specialty Insurance, agreed to acquire a portfolio of luxury hotels from Maps Hotels & Resorts One LLC ("Maps Hotels") for approximately $5.8 billion. After signing, the COVID-19 pandemic devastated the hospitality industry. Hotel occupancy rates plummeted, revenues collapsed, and Maps Hotels took drastic operational actions in response — including mass layoffs, property closures, suspension of capital expenditure programs, and entry into government loan programs — all without obtaining the buyer's prior consent as required by the ordinary course covenant. AB Stable sought to terminate the transaction, invoking both the MAE closing condition and the ordinary course covenant.
Holding. Vice Chancellor Slights found that the pandemic-related financ

MEMORANDUM

PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT

Record

Parties

Dates

Amounts